Royalty Pharma PLC (NASDAQ:RPRX) Holdings Lifted by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC lifted its holdings in shares of Royalty Pharma PLC (NASDAQ:RPRX - Free Report) by 2,543.7% in the 1st quarter, according to its most recent Form 13F filing with the SEC. The firm owned 1,081,128 shares of the biopharmaceutical company's stock after buying an additional 1,040,234 shares during the period. Los Angeles Capital Management LLC owned approximately 0.19% of Royalty Pharma worth $33,656,000 at the end of the most recent quarter.

A number of other large investors also recently bought and sold shares of the company. Louisbourg Investments Inc. purchased a new position in Royalty Pharma in the first quarter valued at about $28,000. MassMutual Private Wealth & Trust FSB increased its holdings in Royalty Pharma by 76.4% in the first quarter. MassMutual Private Wealth & Trust FSB now owns 956 shares of the biopharmaceutical company's stock valued at $30,000 after buying an additional 414 shares in the last quarter. Allworth Financial LP increased its holdings in Royalty Pharma by 41.6% during the 1st quarter. Allworth Financial LP now owns 1,539 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 452 shares in the last quarter. Westpac Banking Corp purchased a new position in Royalty Pharma during the 4th quarter valued at about $53,000. Finally, National Bank of Canada FI increased its holdings in Royalty Pharma by 21.8% during the 4th quarter. National Bank of Canada FI now owns 2,074 shares of the biopharmaceutical company's stock valued at $53,000 after acquiring an additional 371 shares in the last quarter. Hedge funds and other institutional investors own 54.35% of the company's stock.

Wall Street Analyst Weigh In

Several research firms have weighed in on RPRX. Wall Street Zen downgraded shares of Royalty Pharma from a "buy" rating to a "hold" rating in a report on Sunday, June 29th. Citigroup raised their target price on shares of Royalty Pharma from $40.00 to $42.00 and gave the company a "buy" rating in a report on Tuesday. Finally, Morgan Stanley set a $54.00 price target on shares of Royalty Pharma and gave the stock an "overweight" rating in a report on Thursday, July 10th. One investment analyst has rated the stock with a hold rating, three have assigned a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Buy" and a consensus price target of $49.00.

Royalty Pharma Stock Up 1.4%

Shares of RPRX stock traded up $0.49 on Thursday, hitting $36.50. The stock had a trading volume of 606,973 shares, compared to its average volume of 4,524,453. The firm has a market capitalization of $20.52 billion, a price-to-earnings ratio of 19.73, a P/E/G ratio of 2.40 and a beta of 0.50. The stock's 50 day moving average is $34.68 and its 200-day moving average is $32.88. The company has a debt-to-equity ratio of 0.68, a quick ratio of 1.56 and a current ratio of 1.56. Royalty Pharma PLC has a 52-week low of $24.05 and a 52-week high of $36.89.

Royalty Pharma (NASDAQ:RPRX - Get Free Report) last announced its earnings results on Thursday, May 8th. The biopharmaceutical company reported $1.06 earnings per share for the quarter, beating the consensus estimate of $0.99 by $0.07. The business had revenue of $839.00 million during the quarter, compared to the consensus estimate of $724.69 million. Royalty Pharma had a net margin of 48.23% and a return on equity of 24.71%. As a group, research analysts expect that Royalty Pharma PLC will post 4.49 earnings per share for the current year.

Royalty Pharma Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, September 10th. Stockholders of record on Friday, August 15th will be given a $0.22 dividend. This represents a $0.88 annualized dividend and a dividend yield of 2.41%. The ex-dividend date of this dividend is Friday, August 15th. Royalty Pharma's payout ratio is currently 47.57%.

About Royalty Pharma

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.